Papers/PMID:34237387
Effects of chromium supplementation on blood pressure, body mass index, liver function enzymes and malondialdehyde in patients with type 2 diabetes: A systematic review and dose-response meta-analysis of randomized controlled trials.
Complementary therapies in medicine2021The record
6 findings · 1 compound · 6 endpoints · 4 null
What it reported
How to read these marksWhat moved
2 findings
chromium(3+) — decreases diastolic blood pressure (setting unspecified)
Evidence strength: very limited.Findingreplicated ×1“Pooled effect sizes indicated that chromium significantly reduced diastolic blood pressure (DBP) (WMD): -2.36 mmHg, 95 % CI: -4.14, -0.60; P = 0.008), and MDA (WMD: -0.55 umol/l, 95 % CI: -0.96, -0.14; P = 0.008).”
Quoted verbatim from Effects of chromium supplementation on blood pressure, body mass index, liver function enzymes and malondialdehyde in patients with type 2 diabetes: A systematic review and dose-response meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- patients with type 2 diabetes, 15 pooled randomised trials
Effect -2.36 mean difference, 95% CI -4.14 to -0.6
Effects of chromium supplementation on blood pressure, body mass index, liver function enzymes and malondialdehyde in patients with type 2 diabetes: A systematic review and dose-response meta-analysis of randomized controlled trials.2021PMID:3423738710.1016/j.ctim.2021.102755Permalink
chromium(3+) — decreases malondialdehyde (circulating)
Evidence strength: very limited.Findingreplicated ×1“Pooled effect sizes indicated that chromium significantly reduced diastolic blood pressure (DBP) (WMD): -2.36 mmHg, 95 % CI: -4.14, -0.60; P = 0.008), and MDA (WMD: -0.55 umol/l, 95 % CI: -0.96, -0.14; P = 0.008).”
Quoted verbatim from Effects of chromium supplementation on blood pressure, body mass index, liver function enzymes and malondialdehyde in patients with type 2 diabetes: A systematic review and dose-response meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- patients with type 2 diabetes, 15 pooled randomised trials
Effect -0.55 mean difference, 95% CI -0.96 to -0.14
Effects of chromium supplementation on blood pressure, body mass index, liver function enzymes and malondialdehyde in patients with type 2 diabetes: A systematic review and dose-response meta-analysis of randomized controlled trials.2021PMID:3423738710.1016/j.ctim.2021.102755Permalink
What did not
4 findings
chromium(3+) — no detected effect on body mass index
Evidence strength: very limited.FindingNull resultreplicated ×3“However, chromium supplementation did not significantly affect BMI, systolic blood pressure (SBP), alanine aminotransferase (ALT), aspartate aminotransferase (AST).”
Quoted verbatim from Effects of chromium supplementation on blood pressure, body mass index, liver function enzymes and malondialdehyde in patients with type 2 diabetes: A systematic review and dose-response meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- patients with type 2 diabetes, 15 pooled randomised trials
Effects of chromium supplementation on blood pressure, body mass index, liver function enzymes and malondialdehyde in patients with type 2 diabetes: A systematic review and dose-response meta-analysis of randomized controlled trials.2021PMID:3423738710.1016/j.ctim.2021.102755Permalink
chromium(3+) — no detected effect on alanine aminotransferase
Evidence strength: very limited.FindingNull result“However, chromium supplementation did not significantly affect BMI, systolic blood pressure (SBP), alanine aminotransferase (ALT), aspartate aminotransferase (AST).”
Quoted verbatim from Effects of chromium supplementation on blood pressure, body mass index, liver function enzymes and malondialdehyde in patients with type 2 diabetes: A systematic review and dose-response meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- patients with type 2 diabetes, 15 pooled randomised trials
Effects of chromium supplementation on blood pressure, body mass index, liver function enzymes and malondialdehyde in patients with type 2 diabetes: A systematic review and dose-response meta-analysis of randomized controlled trials.2021PMID:3423738710.1016/j.ctim.2021.102755Permalink
chromium(3+) — no detected effect on aspartate aminotransferase
Evidence strength: very limited.FindingNull resultreplicated ×1“However, chromium supplementation did not significantly affect BMI, systolic blood pressure (SBP), alanine aminotransferase (ALT), aspartate aminotransferase (AST).”
Quoted verbatim from Effects of chromium supplementation on blood pressure, body mass index, liver function enzymes and malondialdehyde in patients with type 2 diabetes: A systematic review and dose-response meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- patients with type 2 diabetes, 15 pooled randomised trials
Effects of chromium supplementation on blood pressure, body mass index, liver function enzymes and malondialdehyde in patients with type 2 diabetes: A systematic review and dose-response meta-analysis of randomized controlled trials.2021PMID:3423738710.1016/j.ctim.2021.102755Permalink
chromium(3+) — no detected effect on systolic blood pressure (setting unspecified)
Evidence strength: very limited.FindingNull resultreplicated ×1“However, chromium supplementation did not significantly affect BMI, systolic blood pressure (SBP), alanine aminotransferase (ALT), aspartate aminotransferase (AST).”
Quoted verbatim from Effects of chromium supplementation on blood pressure, body mass index, liver function enzymes and malondialdehyde in patients with type 2 diabetes: A systematic review and dose-response meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- patients with type 2 diabetes, 15 pooled randomised trials
Effects of chromium supplementation on blood pressure, body mass index, liver function enzymes and malondialdehyde in patients with type 2 diabetes: A systematic review and dose-response meta-analysis of randomized controlled trials.2021PMID:3423738710.1016/j.ctim.2021.102755Permalink